SNY Sep 2024 30.000 call
| Previous close | 20.05 |
| Open | 20.05 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 30.00 |
| Expiry date | 2024-09-20 |
| Day's range | 20.05 - 20.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
BloombergNovavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from BloombergBiden Set to Impose Tariffs on China EVs, Strategic SectorsApple Apologizes for iPad Pro Ad, Scraps Plan to Air It on TVAckman Scolded Over DEI Views at Closed-Door Milken SessionMarjorie Taylor Greene Finally Got What She Deserved: Defeat‘Seriously Underwater’ Home Mortgages Tick Up Across the US
Barrons.comNovavax Stock Surges 120% on $1.4 Billion Deal With Sanofi
Novavax the pharmaceutical company that last year warned that falling sales of its Covid-19 vaccine could put it out of business, said it reached a $1.4 billion deal with French company Sanofi to commercialize its existing treatment and develop a new one. Shares spiked 120% in premarket trading to $10.02. Sanofi agreed to pay $500 million upfront and spend another $700 million when the company hits development, regulatory and launch milestones, Novavax said in a statement Friday.
Yahoo Finance UKTrending tickers: TSMC, Novavax, Anglo American and IAG
The latest investor updates on stocks that are trending on Friday
